Abstract: Herein is reported a polypeptide-polynucleotide-complex as therapeutic agent and its use as tool for the targeted delivery of an effector moiety. The polynucleotide part of the complex is essentially resistant to proteolytic and enzymatic degradation in vivo. Additionally the polypeptide part specifically binds to a compound or structure such as a tissue or organ, a process or a disease. Thus, one aspect as reported herein is a polypeptide-polynucleotide-complex comprising a) a polypeptide specifically binding to a target and conjugated to a first member of a binding pair, b) a polynucleotide linker conjugated at its first terminus to the second member of the binding pair, and c) an effector moiety conjugated to a polynucleotide that is complementary to at least a part of the polynucleotide linker.

Abstract: Herein is reported an IgG class Fc-region comprising a first variant Fc-region polypeptide and a second variant Fc-region polypeptide, wherein the first variant Fc-region polypeptide is derived from a first parent IgG class Fc-region polypeptide and the second variant Fc-region polypeptide is derived from a second parent IgG class Fc-region polypeptide, whereby the first parent IgG class Fc-region polypeptide is identical to or different from the second parent IgG class Fc-region polypeptide, and the first variant Fc-region polypeptide differs from the second variant Fc-region polypeptide in one or more amino acid residues other than those amino acid residues in which the first parent IgG class Fc-region polypeptide differs from the second parent IgG class Fc-region polypeptide, and the IgG class Fc-region comprising the first variant Fc-region polypeptide and the second variant Fc-region peptide has an affinity to a human Fc-receptor that is different than that of an IgG class Fc-region comprising the first

Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The present invention relates to multispecific antibodies, methods for their production, pharmaceutical compositions containing said antibodies and uses thereof.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: A method for producing at least one spring contact pin acting as an electrical contact, or a spring contact pin arrangement comprises at least one such spring contact pin. The following steps are provided: producing at least one base part of the spring contact pin, at least one section of said base part being made of plastic, and subsequently metallizing at least the section of the base part that is made of plastic. The invention also relates to a spring contact pin produced to according to said method, or a spring contact pin arrangement having at least one such spring contact pin.

Abstract: The present invention relates to monovalent antigen binding proteins with a CH1-CL domain exchange, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Abstract: The present invention relates to antibodies and Fc-region fusion polypeptides which are asymmetrically modified with respect to their Fc-receptor, especially their FcRn, and methods of using the same.

Abstract: The present invention relates to bispecific HER2 antibodies, novel HER2 antibody variants, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Abstract: A method for decorating substrates, in particular packaging, comprising the steps: printing at least one first decorative pattern (2) on the substrate using a first radiation-curable, preferably UV-curable, printing ink composition (3); printing at least one second decorative pattern (4), using a second radiation-curable, preferably UV-curable, printing ink composition (5), on at least part of the substrate (1) in a region near to the first pattern (2), chronologically before, after, or during the printing of the first pattern; radiation curing of the first and second printing ink compositions (3, 5), preferably directly after the printing of each pattern, the radiation-cured second printing ink composition having a lower glass transition temperature than the radiation-cured first printing ink composition; application of a decorative coating to the second pattern by means of a hot foil stamping process, a hot stamping foil comprising a decorative coating material being pressed against the printed substrate by

Abstract: Multispecific antibodies based on antibodies that share a common light chain are described herein. The multispecific antibodies include: modified heavy chains having, by domain exchange, a common light chain variable domain VL; and two modified light chains having, by domain exchange, variable heavy chain domains of a first antibody (VH1) and a second antibody (VH2), wherein one light chain is of kappa isotype and one light chain is of lambda isotype. The present invention also relates to methods for the manufacture of such antibodies and their use.

Abstract: The present invention relates to nucleic acids which encode the heavy chains and light chains of a novel domain exchanged, bivalent, bispecific antibody, and vectors comprising the same.

Abstract: A bispecific bi- or trivalent antibody specifically binding to the two targets which are extracellular domain of human B cell maturation antigen (BCMA) and human CD3?, wherein the variable domains VL and VH in a light chain and the respective heavy chain are replaced by each other, characterized in comprising a constant domain CL wherein the amino acid at position 124 is substituted independently by lysine (K), arginine (R) or histidine (H) (numbering according to Kabat), and in the respective constant domain CH1 the amino acid at position 147 and the amino acid at position 213 is substituted independently by glutamic acid (E), or aspartic acid (D) (numbering according to EU index of Kabat). Also the manufacture and use of said antibody.

Abstract: The present invention relates to nucleic acids which encode the heavy chains and light chains of a novel domain exchanged, bivalent, bispecific antibody, and vectors comprising the same.

Abstract: The present invention relates to antigen binding proteins comprising two Fc parts, methods for their production, pharmaceutical compositions containing said antigen binding proteins, and uses thereof.

Abstract: The present invention generally relates to bispecific antigen binding molecules for activating T cells, more particularly bispecific antigen binding molecules for activating T cells targeting the Robo 4 receptor. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease. In addition, the invention also relates to antibodies that specifically bind to Robo 4.

Abstract: A method for producing at least one spring contact pin acting as an electrical contact, or a spring contact pin arrangement comprises at least one such spring contact pin. The following steps are provided: producing at least one base part of the spring contact pin, at least one section of said base part being made of plastic, and subsequently metallizing at least the section of the base part that is made of plastic. The invention also relates to a spring contact pin produced to according to said method, or a spring contact pin arrangement having at least one such spring contact pin.

Abstract: Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.

Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.